報價延遲最少15分鐘:2026/03/04 11:29 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
28.055 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.03/0.66
|
|
企業價值
2.94B
|
| 資產負債 |
|
每股賬面淨值
1.24
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
490.73M
|
|
每股收益
2.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body. |
